30 closest matches · ranked by relevance
Healthy
Primary: Quality of Aspirate Specimen Yield Total Score -Jamshidi Manual Standard Device — 4.83; 5.75; 1.5; 1.5 units on a scale
Bone Marrow Aspiration and Biopsy Specimen Collection
Primary: Percent of Hematopoietic Tissue Present in Bone Marrow Biopsy Specimens Obtained Using the Manual Device and Powered Device — 42.5; 55.8 % Hematopoetic tissue present…
Bone Marrow Biopsy Procedures
Primary: Subject Reported Level of Pain During Procedure — 3.8; 3.2 units on a scale
Plasma Cell Myeloma
Primary: Bone Marrow Core Biopsy Length (in mm) and Artifacts Assessed by the Pathologist — 14; 9.5 Millimeters
Multiple Myeloma
Primary: Days Until Neutrophil Recovery Following Peripheral Blood Stem Cell Transplant Minus the Historical Median Day Until Recovery. — 0 Days — p=<0.025
Plasma Cell Myeloma · Multiple Myeloma
Primary: Percentage of Patients Achieving at Least 2 x 10^6 Cluster of Differentiation 34 (CD34) Cells Per Kg Recipient Body Weight on Day 1 of Apheresis — 98 percentage of…
Peripheral Artery Disease · Vascular Disease · Critical Limb Ischemia
Primary: Number of Participants With Treatment-related Adverse Events Occurring During the Enrollment Period as Assessed by the Investigator Using the CTCAE 4.0 Scale. — 2; 0…
Granulocyte/ Polymorphonuclear Cells
Primary: Granulocyte/PMN Cell Collection Efficiency — 54.7; 52.4; 41.9; 44.7 percent cells processed
Knee Osteoarthritis
Primary: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Measurements — 32.1; 35.3; 19.5; 19.8 score on a scale
Bone Diseases
Primary: Resorption of Graft Material (GR) Compared at 24 Months — 51; 47 percentage of resorption — p=<0.01
Lumbar Degenerative Disc Disease
Primary: Spinal Fusion Grade at 1 Year Via CT Scan — 1.67; 2.4 score on a scale
Leukemia · Myeloproliferative Disorders · Myelodysplastic-Myeloproliferative Diseases
Primary: Two-year Overall Survival — 46; 51 percentage of patients
Healthy Stem Cell Donor · No Evidence of Disease
Primary: Percentage of Participants With Short-term Adverse Events in G-CSF (Filgrastim) Stimulated Bone Marrow (G-BM) Donors — 0 Percentage of patients
Healthy Apheresis Donors · Mononuclear (MNC) Cell Donors
Primary: CD34+ Collection Efficiency (CE1 %) — 87.7; 81.4; 66.6; 65.8 percent
Leukapheresis
Primary: Mononuclear Cell Collection Efficiency — 61; 57 % of processed MNCs that were collected
Ischemic Stroke
Primary: Study Related Serious Adverse Events (SR-SAE) — 0 Events
Breast Cancer Female
Primary: Procedural Time — 38.44 Minutes
Sickle Cell Disease
Primary: Number of Participants With Sufficient Collection of Hemopoietic Stem Cells (HSCs) Without Serious Adverse Events — 14 Participants
Pulmonary Infiltrate New
Primary: Number of Patients With Positive Culture or Molecular Results After Brochoscopy — 40 participants
Myeloproliferative Disorders · Acute Myelogenous Leukemia · Chronic Myelogenous Leukemia
Primary: Number of Participants Who Experienced Transplant Related Mortality — 5; 4 Participants
Hematological Malignancies
Primary: Percentage Change in Bone Mineral Density From Baseline to 6 and 12 Months — 0.06; -2.61; -3.63; -4.85 Percentage change
Lung Diseases
Primary: Number of Participants With Serious Adverse Events — 0 Participants
Tooth Loss
Primary: Bone Mineral Density of Bone Core — .79; .78 mg/mm^3
Intraosseous Vascular Access
Primary: Occurrences of Extravasation During Infusion — 2 participants
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Myeloid, Acute · Burkitt Lymphoma
Primary: Overall Survival at 180 Days From the Time of Transplant — 83.7; 62.0 percentage of participants
Healthy
Primary: Change in Cytokine Gene Expression Profiles (84 Genes) in T Cells Following G-CSF Administration — 16 unique cytokine genes affected
Sickle Cell Disease
Primary: Event -Free Survival Rate — 19 Participants
Osteoporosis · Fractures, Bone
Primary: Correlation Between NTX Measures With Each Other — 0.52 r-value — p=<0.001
Myeloma · Lymphoma
Primary: Patients Achieving Greater Than or Equal to 5 x 10^6 of CD34+ Cells/kg in a Single Day of Apheresis — 9; 17 participants
Allogeneic Hematopoietic Stem Cell Transplantation
Primary: Number of Participants Providing Biologic Samples — 1709 Participants